Evidence map›Paper›PMID 33996040›Full record

ArticleJournal of nutritional science2021

Incidence of relapse following a new approach to simplifying and optimising acute malnutrition treatment in children aged 6-59 months: a prospective cohort in rural Northern Burkina Faso.

Maguy Daures, Kevin Phelan, Mariama Issoufou, Ousmane Sawadogo, Bruno Akpakpo, Moumouni Kinda, Susan Shepherd, Renaud Becquet

Open access · goldAbstract read
In one paragraph

Article in Journal of nutritional science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Maguy DauresUniversity of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.ORCID 0000-0003-2878-4524
Kevin PhelanThe Alliance for International Medical Action (ALIMA), Paris, France.
Mariama IssoufouThe Alliance for International Medical Action (ALIMA), Yako, Burkina Faso.
Ousmane SawadogoAssociation KEOOGO, Ouagadougou, Burkina Faso.
Bruno AkpakpoThe Alliance for International Medical Action (ALIMA), Yako, Burkina Faso.
Moumouni KindaThe Alliance for International Medical Action (ALIMA), Dakar, Senegal.
Susan ShepherdThe Alliance for International Medical Action (ALIMA), Dakar, Senegal.
Renaud BecquetUniversity of Bordeaux, Inserm, French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center, Team IDLIC, UMR 1219, Bordeaux, France.
Alliance for International Medical Action · SNUniversité de Bordeaux · FRAssociation Keoogo · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to determine the 3-month incidence of relapse and associated factors among children who recovered under the Optimising treatment for acute MAlnutrition (OptiMA) strategy, a MUAC-based protocol. A prospective cohort of children successfully treated for acute malnutrition was monitored between April 2017 and February 2018. Children were seen at home by community health workers (CHWs) every 2 weeks for 3 months. Relapse was defined as a child who had met OptiMA recovery criteria (MUAC ≥ 125 mm for two consecutive weeks) but subsequently had a MUAC < 125 mm at any home visit. Cumulative incidence and incidence rates per 100 child-months were estimated. Multivariable survival analysis was conducted using a shared frailty model with a random effect on health facilities to identify associated factors. Of the 640 children included, the overall 3-month cumulative incidence of relapse was 6⋅8 % (95 % CI 5⋅2, 8⋅8). Globally, the incidence rate of relapse was 2⋅5 (95 % CI 1⋅9, 3⋅3) per 100 child-months and 3⋅7 (95 % CI 1⋅9, 6⋅8) per 100 child-months among children admitted with a MUAC < 115 mm. Most (88⋅6 %) relapses were detected early when MUAC was between 120 and 124 mm. Relapse was positively associated with hospitalisation, with an adjusted hazard ratio (aHR) of 2⋅06 (95 % CI 1⋅01, 4⋅26) for children who had an inpatient stay at any point during treatment compared with children who did not. The incidence of relapse following recovery under OptiMA was relatively low in this context, but the lack of a standard relapse definition does not allow for comparison across settings Closer follow-up with caretakers whose children are admitted with MUAC < 115 mm or required hospitalisation during treatment should be considered in managing groups at high risk of relapse. Training caretakers to screen their children for relapse at home using MUAC could be more effective at detecting early relapse, and less costly, than home visits by CHWs.

Indexed as

MalnutritionSevere Acute MalnutritionBurkina FasoChild, PreschoolHumansIncidenceInfantProspective StudiesRecurrenceAcute malnutritionaHR, adjusted hazard ratioAM, acute malnutritionChildrenCHWs, community health workersCIs, confidence intervalsCORTASAM, Council of Research & Technical Advice on Acute MalnutritionHAZ, height-for-age Z-scoreIncidenceIQR, interquartile rangeMAM, moderate acute malnutritionMUAC-based and reduced doses protocolMUAC, mid-upper arm circumferenceOptiMA, Optimising treatment for acute MAlnutritionRDT, rapid diagnostic testsRelapseRUTF, ready-to-use therapeutic foodSAM, severe acute malnutritionsd, standard deviationWest AfricaWHO, World Health OrganizationWHZ, weight-for-height Z-score

Identifiers

PMID33996040
PMCPMC8080230
OpenAlexW3153205263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.